See more : Anzu Special Acquisition Corp I (ANZU) Income Statement Analysis – Financial Results
Complete financial analysis of NeutriSci International Inc. (NRXCF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NeutriSci International Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- HUANLEJIA Food Group Co., Ltd. (300997.SZ) Income Statement Analysis – Financial Results
- IMI plc (IMIAY) Income Statement Analysis – Financial Results
- Stockmann Oyj Abp (STOCKA.HE) Income Statement Analysis – Financial Results
- Network International Holdings plc (NETW.L) Income Statement Analysis – Financial Results
- Veerkrupa Jewellers Limited (VEERKRUPA.BO) Income Statement Analysis – Financial Results
NeutriSci International Inc. (NRXCF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.neutrisci.com
About NeutriSci International Inc.
NeutriSci International Inc. develops, markets, and distributes nutraceutical products in Canada, the United States, Europe, Asia, and South America. It offers neuenergy, an energy tablet designed to deliver enhanced focus and mental clarity. The company sells its products through a distribution network of retail and online channels. NeutriSci International Inc. has partnership with LaSanta Botanicals, Nutritional High, and Naturally Splendid. NeutriSci International Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 457.75K | 80.89K | 74.57K | 96.54K | 82.66K | 151.07K | 125.35K | 27.79K | 0.00 | 0.00 | 274.80K | 218.48K | 488.17K | 311.42K | 630.46K | 390.07K | 62.00K | 101.44K | 1.99K | 2.39K | 4.48K |
| Cost of Revenue | 501.16K | 101.44K | 80.44K | 93.60K | 78.75K | 161.73K | 99.94K | 47.72K | 0.00 | 0.00 | 116.31K | 111.16K | 324.22K | 148.85K | 0.00 | 0.00 | 83.19K | 128.07K | 1.47K | 0.00 | 0.00 |
| Gross Profit | -43.41K | -20.55K | -5.87K | 2.94K | 3.91K | -10.66K | 25.42K | -19.93K | 0.00 | 0.00 | 158.49K | 107.32K | 163.95K | 162.56K | 630.46K | 390.07K | -21.20K | -26.63K | 526.00 | 2.39K | 4.48K |
| Gross Profit Ratio | -9.48% | -25.40% | -7.87% | 3.04% | 4.73% | -7.05% | 20.28% | -71.69% | 0.00% | 0.00% | 57.68% | 49.12% | 33.58% | 52.20% | 100.00% | 100.00% | -34.19% | -26.26% | 26.39% | 100.00% | 100.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 458.69K | 616.49K | 598.23K | 746.35K | 894.23K | 604.31K | 261.99K | 260.01K | 264.37K | 0.00 | 0.00 |
| General & Administrative | 600.23K | 1.25M | 1.71M | 1.42M | 1.72M | 1.55M | 2.04M | 1.91M | 310.32K | 153.43K | 424.69K | 368.62K | 447.12K | 511.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | -3.96K | 71.65K | 205.36K | 229.54K | 543.94K | 519.35K | 532.23K | 417.42K | 0.00 | 0.00 | 641.78K | 468.37K | 343.42K | 685.83K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 596.27K | 1.32M | 1.91M | 1.65M | 2.26M | 2.07M | 2.57M | 2.33M | 310.32K | 153.43K | 1.07M | 836.98K | 790.54K | 1.20M | 2.76M | 1.58M | 1.64M | 2.19M | 702.84K | 20.47K | 0.00 |
| Other Expenses | -639.68K | 24.52K | 0.00 | 0.00 | 0.00 | 28.17K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | -43.41K | 1.37M | 1.94M | 1.65M | 2.28M | 2.08M | 2.61M | 2.35M | 310.32K | 153.43K | 1.54M | 1.47M | 1.41M | 1.97M | 3.68M | 2.20M | 1.92M | 2.50M | 981.75K | 20.47K | 19.80K |
| Cost & Expenses | 1.21M | 1.47M | 2.02M | 1.75M | 2.36M | 2.24M | 2.71M | 2.39M | 310.32K | 153.43K | 1.66M | 1.58M | 1.73M | 2.12M | 3.68M | 2.20M | 2.00M | 2.63M | 983.22K | 20.47K | 19.80K |
| Interest Income | 0.00 | 1.00K | 1.38K | 1.18K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.13K | 15.13K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 1.00K | 1.38K | 1.18K | 500.00 | 28.52K | 61.23K | 56.63K | 134.31K | 1.41M | 1.11M | 782.42K | 514.29K | 259.20K | 12.33K | 12.33K | 0.00 | 0.00 | 27.99K | 27.99K | 0.00 |
| Depreciation & Amortization | 37.26K | 45.11K | 27.30K | 5.04K | 3.80K | 10.44K | 15.55K | 12.48K | -620.65K | -1.71M | 15.47K | 17.07K | 19.11K | 22.90K | 24.98K | 13.92K | 14.85K | 50.11K | 14.55K | 0.00 | -30.65K |
| EBITDA | -733.43K | -1.53M | -1.92M | -1.61M | -2.36M | -2.08M | -2.49M | -3.67M | -4.93M | -310.32K | -1.37M | -74.45K | -1.35M | -1.22M | -1.78M | -3.02M | -1.81M | -1.93M | -2.48M | -966.68K | -18.08K |
| EBITDA Ratio | -160.23% | -1,630.02% | -2,570.63% | -1,705.46% | -2,729.19% | -1,360.04% | -2,050.48% | -8,470.77% | 0.00% | 0.00% | -497.33% | -616.14% | -250.90% | -571.84% | -479.04% | -460.41% | -3,106.89% | -2,446.21% | -48,503.61% | -757.71% | -342.03% |
| Operating Income | -750.58K | -1.36M | -1.94M | -1.65M | -2.26M | -2.07M | 2.59M | 2.33M | 310.32K | 1.56M | 1.38M | 1.36M | 1.24M | -1.80M | 3.05M | -1.81M | 1.94M | 2.53M | 981.23K | -18.08K | 15.32K |
| Operating Income Ratio | -163.97% | -1,685.78% | -2,607.24% | -1,710.67% | -2,733.79% | -1,366.95% | 2,062.89% | 8,383.57% | 0.00% | 0.00% | 502.96% | 623.96% | 254.81% | -579.19% | 483.00% | -463.98% | 3,130.85% | 2,495.61% | 49,233.62% | -757.71% | 342.03% |
| Total Other Income/Expenses | -20.11K | -69.49K | -8.33K | 36.71K | -7.82K | -29.02K | 21.02K | -11.00K | -3.80M | -1.87M | -3.88M | -2.55M | -3.39M | -1.24M | 0.00 | 2.50K | -42.14K | -1.94M | -2.53M | -182.09K | 18.08K |
| Income Before Tax | -770.69K | -1.57M | -1.95M | -1.61M | -2.38M | -2.12M | -2.56M | -4.01M | -389.08K | -1.56M | -2.49M | 0.00 | 0.00 | 0.00 | 0.00 | -1.81M | 1.90M | 2.29M | 0.00 | -200.17K | 0.00 |
| Income Before Tax Ratio | -168.37% | -1,943.53% | -2,618.34% | -1,670.71% | -2,882.67% | -1,404.81% | -2,046.12% | -14,411.20% | 0.00% | 0.00% | -907.23% | 0.00% | 0.00% | 0.00% | 0.00% | -463.34% | 3,062.87% | 2,258.22% | 0.00% | -8,389.40% | 0.00% |
| Income Tax Expense | 0.00 | 25.52K | 1.38K | 1.18K | 16.79K | 56.69K | 61.23K | 56.63K | 754.95K | -4.94M | -2.76M | 782.42K | 514.29K | 259.20K | -2.80K | 0.00 | 0.00 | 0.00 | 27.99K | 88.00 | 30.65K |
| Net Income | -770.69K | -1.57M | -1.95M | -1.61M | -2.38M | -2.12M | -2.56M | -4.01M | -389.08K | 7.91M | -2.49M | -2.15M | -1.76M | -2.06M | -3.04M | -1.81M | -1.98M | -2.77M | -1.01M | -200.26K | -15.32K |
| Net Income Ratio | -168.37% | -1,943.53% | -2,618.34% | -1,670.71% | -2,882.67% | -1,404.81% | -2,046.12% | -14,411.20% | 0.00% | 0.00% | -907.23% | -982.07% | -360.16% | -662.43% | -482.56% | -463.34% | -3,198.82% | -2,733.00% | -50,638.03% | -8,393.08% | -342.03% |
| EPS | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | -0.10 | -0.05 | 2.43 | -0.77 | -0.66 | -0.54 | -0.64 | -0.98 | -0.71 | -1.52 | -3.71 | -2.30 | -2.88 | -0.11 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 | -0.03 | -0.04 | -0.10 | -0.05 | 2.43 | -0.77 | -0.66 | -0.54 | -0.64 | -0.98 | -0.71 | -1.52 | -3.71 | -2.30 | -2.88 | -0.11 |
| Weighted Avg Shares Out | 166.15M | 158.59M | 143.38M | 116.02M | 101.66M | 81.83M | 59.98M | 40.61M | 7.62M | 3.26M | 3.26M | 3.26M | 3.26M | 3.22M | 3.09M | 2.54M | 1.30M | 746.79K | 439.24K | 69.44K | 138.89K |
| Weighted Avg Shares Out (Dil) | 166.15M | 158.59M | 143.38M | 116.02M | 101.66M | 81.83M | 59.98M | 40.61M | 7.62M | 3.26M | 3.26M | 3.26M | 3.26M | 3.22M | 3.09M | 2.54M | 1.30M | 746.79K | 439.24K | 69.44K | 138.89K |
Neutrisci Announces New State-Of-The-Art Production and Research Facility in Las Vegas, Nevada, USA
VANCOUVER, BC / ACCESSWIRE / March 18, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSX-V:NU)(OTCQB:NRXCF)(FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is very pleased to announce the completion of its newly dedicated production line...
NeutriSci: Harmonized Code Approval Received by TABLETZ LLC., in Japan
VANCOUVER, BC / ACCESSWIRE / March 8, 2021 / NeutriSci International Inc. ("NeutriSci" or the "Company") (TSXV:NU)(OTCQB:NRXCF)(FRA:1N9), an innovative technology company developing products for the nutraceutical industry, in conjunction with its partner, Tabletz LLC, is very pleased to announce that its...
Source: https://incomestatements.info
Category: Stock Reports